Replies to post #90348 on Biotech Values

[DewDiligence]

jbog et al Re: D-mab and ONJ

In the three completed trials of D-mab vs Zometa in metastatic cancer (the first three rows of the table in #msg-46432335), the aggregate rate of ONJ is 1.8% for D-mab vs 1.3% for Zometa.